EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Cure of Congenital Purpura Fulminans via Expression of Engineered Protein C Through Neonatal Genome Editing in Mice

Tomoki Togashi iD, Nemekhbayar Baatartsogt iD, Yasumitsu Nagao iD, Yuji Kashiwakura iD, Morisada Hayakawa iD, Takafumi Hiramoto, Takayuki Fujiwara iD, Eriko Morishita iD, Osamu Nureki iD, Tsukasa Ohmori iD

Arteriosclerosis, Thrombosis, and Vascular Biology · 2024

DOI: 10.1161/atvbaha.123.319460 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Arteriosclerosis, Thrombosis, and Vascular Biology, 2024. Verfasst von Tomoki Togashi und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Clinical Laboratory Science, Division of Health Sciences, Graduate School of Medical Science, Kanazawa University, Ishikawa, Japan (T.T…. Hauptthemen laut MEDLINE: Protein C, Gene Editing, Mice, Inbred C57BL, Purpura Fulminans. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 55 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: PC (protein C) is a plasma anticoagulant encoded by PROC ; mutation in both PROC alleles results in neonatal purpura fulminans—a fatal systemic thrombotic disorder. In the present study, we aimed to develop a genome editing treatment to cure congenital PC deficiency. METHODS: We generated an engineered APC (activated PC) to insert a furin-cleaving peptide sequence between light and heavy chains. The engineered PC was expressed in the liver of mice using an adeno-associated virus vector or CRISPR/Cas9 (clustered regularly interspaced short palindromic repeats/clustered regularly interspaced short palindromic repeat–associated 9)-mediated genome editing using an adeno-associated virus vector in vivo. RESULTS: The engineered PC could be released in its activated form and significantly prolonged the plasma coagulation time independent of the cofactor activity of PS (protein S) in vitro. The adeno-associated virus vector-mediated expression of the engineered PC, but not wild-type PC, prolonged coagulation time owing to the inhibition of activated coagulation FV (factor V) in a dose-dependent manner and abolished pathological thrombus formation in vivo in C57BL/6J mice. The insertion of EGFP (enhanced green fluorescent protein) sequence conjugated with self-cleaving peptide sequence at Alb locus via neonatal in vivo genome editing using adeno-associated virus vector resulted in the expression of EGFP in 7% of liver cells, mainly via homology-directed repair, in mice. Finally, we succeeded in improving the survival of PC-deficient mice by expressing the engineered PC via neonatal genome editing in vivo. CONCLUSIONS: These results suggest that the expression of engineered PC via neonatal genome editing is a potential cure for severe congenital PC deficiency.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Protein CGene EditingMice, Inbred C57BLPurpura FulminansDisease Models, AnimalDependovirusCRISPR-Cas SystemsGenetic TherapyAnimals, NewbornBlood CoagulationAnimalsGenetic VectorsHumansProtein EngineeringMiceGreen Fluorescent ProteinsProtein C DeficiencyHEK293 Cells

Stichwörter der Autor:innen

furingene therapygenetic diseases, inbornliverthrombosis

Substanzen

Protein CGreen Fluorescent Proteinsenhanced green fluorescent protein

Autor:innen und Institutionen

  • Department of Clinical Laboratory Science, Division of Health Sciences, Graduate School of Medical Science, Kanazawa University, Ishikawa, Japan (T.T., E.M.).
  • Department of Biochemistry, Jichi Medical University School of Medicine, Tochigi, Japan (T.T., N.B., Y.K., M.H., T.H., T.O.).
  • Center for Experimental Medicine (Y.N.), Jichi Medical University, Tochigi, Japan.
  • Center for Gene Therapy Research (Y.K., M.H., T.O.), Jichi Medical University, Tochigi, Japan.
  • Division of Cell and Molecular Medicine Center for Molecular Medicine (T.F.), Jichi Medical University, Tochigi, Japan.
  • Department of Cardiovascular Medicine, The University of Tokyo Hospital, Japan (T.F.).

ORCID-Profile: Tomoki Togashi, Nemekhbayar Baatartsogt, Yasumitsu Nagao, Yuji Kashiwakura, Morisada Hayakawa, Takayuki Fujiwara, Eriko Morishita, Osamu Nureki, Tsukasa Ohmori

Zitieren

APA

Togashi, T., Baatartsogt, N., Nagao, Y., Kashiwakura, Y., Hayakawa, M., Hiramoto, T., Fujiwara, T., Morishita, E., Nureki, O., & Ohmori, T. (2024). Cure of Congenital Purpura Fulminans via Expression of Engineered Protein C Through Neonatal Genome Editing in Mice. Arteriosclerosis, Thrombosis, and Vascular Biology. https://doi.org/10.1161/atvbaha.123.319460

Vancouver

Togashi T, Baatartsogt N, Nagao Y, Kashiwakura Y, Hayakawa M, Hiramoto T, et al. Cure of Congenital Purpura Fulminans via Expression of Engineered Protein C Through Neonatal Genome Editing in Mice. Arteriosclerosis, Thrombosis, and Vascular Biology. 2024. doi:10.1161/atvbaha.123.319460

BibTeX
@article{Togashi2024,
  author = {Togashi, Tomoki and Baatartsogt, Nemekhbayar and Nagao, Yasumitsu and Kashiwakura, Yuji and Hayakawa, Morisada and Hiramoto, Takafumi and Fujiwara, Takayuki and Morishita, Eriko and Nureki, Osamu and Ohmori, Tsukasa},
  title = {Cure of Congenital Purpura Fulminans via Expression of Engineered Protein C Through Neonatal Genome Editing in Mice},
  journal = {Arteriosclerosis, Thrombosis, and Vascular Biology},
  year = {2024},
  doi = {10.1161/atvbaha.123.319460}
}
Kostenlos starten →